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Abstract
Objective—To assess the prevalence, correlates, and age of onset of DSM-IV substance use
disorders (SUDs) among adult inhalant users.
Methods—Analyses were based on structured psychiatric interviews of a nationally representative
sample of 43,093 U.S. adults.
Results—The lifetime prevalence of SUDs among adult inhalant users was 96%. Alcohol (87%),
marijuana (68%), nicotine (58%), cocaine (35%), hallucinogen (31%), and stimulant (28%) use
disorders were more prevalent than inhalant use disorders (19%). An estimated 62% of inhalant users
met criteria for a past-year SUD. Less education, residence in non-metropolitan areas, early onset of
inhalant use, and a history of substance abuse treatment were associated with increased odds of having
an inhalant use disorder. Inhalant users who were under age 30 or who were members of families
with low incomes had increased odds of having nicotine dependence and an alcohol or drug use
disorder in the past year. Compared with substance users without a history of inhalant use, inhalant
users, on average, initiated use of cigarettes, alcohol, and almost all other drugs at younger ages, and
had a higher lifetime prevalence of nicotine, alcohol, and any drug use disorder.
Conclusions—Lifetime and past-year SUDs are prevalent among adults with a history of inhalant
use.
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1. Introduction
In 2005, approximately 877,000 Americans aged 12 years or older used inhalants for the first
time within the past 12 months, 28% of whom were adults aged 18 years or older when they
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first used inhalants (Substance Abuse and Mental Health Services Administration, 2006).
While it is known that inhalant use is associated with cardiac, renal, hepatic, and neurological
morbidity and mortality (Anderson and Loomis, 2003), less is known about the prevalence and
correlates of substance use disorders (SUDs) among adult inhalant users—the focus of this
study.
Studies of inhalant use have typically focused on youth, high-risk subgroups, or convenience
samples (Compton et al., 1994; Fendrich et al., 1997; Sakai et al., 2004). These investigations,
in general, have identified detrimental health and social conditions associated with inhalant
use, including use and abuse of other substances. Wu and Ringwalt (2006) found that 8% of
past-year adult inhalant users met criteria for an inhalant use disorder (IUD) and that inhalant
use was associated with use of multiple drugs. More recently, Wu and Howard (2007a)
examined adult inhalant users in the National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC) and found that, among adults who reported a history of inhalant use,
70% met criteria for one or more lifetime personality, mood, or anxiety disorders, and 38%
had experienced a mood or anxiety disorder in the past year.
The present study adds to the findings from prior studies of adult samples (Compton et al.,
1994; Wu and Ringwalt, 2006; Wu and Howard, 2007a) by addressing gaps in our knowledge
of patterns of SUDs in a representative sample of adult inhalant users. We examined the
following questions: Are specific SUDs prevalent among adults with a history of inhalant use?
Do inhalant users initiate inhalant use at younger ages than their initiation of other drug use?
Do inhalant users start their substance use at younger ages than do substance users without a
history of inhalant use? What subgroups of inhalant users have comparatively high odds of
experiencing SUDs? Because prior studies indicate sex differences in inhalant use and




The NESARC is a longitudinal investigation of a nationally representative sample of 43,093
U.S. adult residents (Grant et al., 2004). It is the largest comorbidity study ever conducted.
NESARC’s target population was the civilian, non-institutionalized adult residents of all 50
states and the District of Columbia. Respondents were selected to participate in NESARC using
a multistage sampling design. To increase the accuracy of national estimates for subgroups,
Hispanics, African Americans, and respondents aged 18–24 years were oversampled. The
overall survey response rate was 82%. Detailed designs of the NESARC are reported elsewhere
(Grant et al., 2004).
2.2. Study variables
Drug use refers to the use of illicit drugs or the nonmedical use of prescription drugs (use
without a doctor’s prescription, in greater amounts, more often, or longer than prescribed).
Respondents were asked whether they have ever used each of nine categories of drugs,
including sedatives, tranquilizers, opioids, stimulants, marijuana, inhalants, cocaine/crack,
hallucinogens, and heroin. Inhalant use was assessed by the question: “Have you EVER used
inhalants or solvents, for example amyl nitrite, nitrous oxide, glue, toluene, or gasoline?”
Participants who responded affirmatively to this question completed additional inhalant-
specific items assessing use in the prior 12 months, recency of use, symptoms of IUD, and age
at first use of any inhalant. Age at first use of other drugs was also recorded. Age of first alcohol
use was defined as the age when the respondent started drinking, not counting small tastes or
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sips. For tobacco use (cigarettes, cigars, a pipe, snuff, or chewing tobacco), we examined age
of first cigarette use because 94% of tobacco users in NESARC smoked cigarettes.
Substance use disorders (SUDs) were assessed with the Alcohol Use Disorders and Associated
Disabilities Interview Schedule–Diagnostic and Statistical Manual of Mental Disorders–
Fourth Revision (AUDADIS-DSM-IV). We examined alcohol use disorders (AUDs), nicotine
dependence (ND), and nine specific drug use disorders (DUDs) (inhalants, marijuana, cocaine,
heroin, hallucinogens, opioids, sedatives, stimulants, and tranquilizers). A binary DUD
variable was defined to identify respondents who met abuse or dependence criteria for any of
the nine DUDs. We also created a variable to summarize the number of the 11 SUDs (AUDs,
ND, and nine specific DUDs) that respondents had experienced.
A history of substance abuse treatment was defined as having ever used any treatment or service
for alcohol or drug use at any location (Wu and Howard, 2007a). A family history of
psychopathology included any self-reported, positive family history of alcohol or drug use
problems, depression, or antisocial behavior among any of the respondent’s biological family
members (Wu and Howard, 2007a). We also examined respondents’ age, sex, race/ethnicity,
education, marital status, annual family income, and area of residence (urbanicity).
2.3. Statistical analysis
Statistical analysis was conducted on the public-use data file of the 2001–2002 NESARC.
Sample characteristics are reported in details elsewhere (Grant et al., 2004). Data were
weighted and analyzed with SUDAAN software (Research Triangle Institute, 2002). We
conducted logistic regression procedures to identify correlates of SUDs among all inhalant
users.
3. Results
3.1. SUDs among inhalant users
Of all respondents aged 18–98 years (N = 43,093), 1.7% (N = 664) reported a history of inhalant
use (lifetime use). Overall, 96% of lifetime inhalant users met criteria for one SUD, and close
to one in five (19%) developed an IUD (Table 1). Sex differences were observed, with men
displaying higher lifetime prevalence rates than women of marijuana, cocaine, sedative, and
tranquilizer use disorders.
3.2. SUDs among non-inhalant users
As shown in Fig. 1, lifetime prevalences of SUDs were significantly higher among lifetime
inhalant users compared with drug users without a history of inhalant use and respondents
without a history of inhalant and other drug use (χ2 test, p < 0.001 for each comparison).
3.3. Mean age at first inhalant use and other substance use
Table 2 indicates that inhalant users had an earlier mean age of first use for all the other
substances (except heroin) than substance users without a history of inhalant use (t-tests, p <
0.001 for each comparison).
3.4. Correlates of lifetime SUDs among inhalant users
As shown Table 3, less than a high school education, onset of inhalant use before age 18,
residence in non-metropolitan areas, and a history of substance abuse treatment were associated
with increased odds of having a lifetime IUD.
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Increased odds of lifetime AUD were noted among inhalant users who were aged 30–44 years,
male, currently married, and among those with a family income under $75,000. Male sex, low
family incomes, early onset of inhalant use (13–17 years), and a family history of
psychopathology were associated with increased odds of lifetime DUD. Increased odds of
lifetime ND were associated with being aged 18–29 years, having a family income under
$75,000, and early onset of inhalant use.
3.5. Correlates of past-year SUDs among inhalant users
Table 4 reports the correlates of past-year SUDs. Young adults and those with low family
incomes had increased odds of having a past-year ND, AUD, or DUD. Male sex was associated
with greater odds of having a past-year AUD, and high school education was associated with
having a DUD. Being white and early inhalant use were associated with increased odds of
having a past-year ND.
4. Discussion
Most (96%) lifetime inhalant users in this adult sample met criteria for at least one lifetime
SUD. Nearly two thirds of lifetime inhalant users met criteria for a past-year SUD. These
findings suggest that inhalant users have a tendency to use multiple substances and are at risk
for developing multiple SUDs (Compton et al., 1994; Dinwiddie et al., 1991).
We found that inhalant users were characterized by early use of cigarettes, alcohol, and
marijuana, which might explain the high prevalence of SUDs (e.g., Grant and Dawson,
1998). Early users of substances might have more time to progress from initial use to disorder
onset than users who start substance use at a later age. Early substance use also tends to co-
occur with multiple risk behaviors (DuRant et al., 1999).
There is a possibility that (a) early individual or environmental risk factors, (b) co-occurrences
of substance use with other risk behaviors, and (c) neurotoxic effects of substance use on brain
(Rogers and Robbins, 2001) place some inhalant users at risk for using multiple substances
and developing SUDs. The vulnerability to SUDs may depend on whether risk characteristics
are aggregated (e.g., McGue and Iacono, 2005; Newcomb and Felix-Ortiz, 1992). Although
this cross-sectional study cannot determine causality, these findings suggest that a general
mechanism of risk might explain the association between inhalant use and multiple SUDs (e.g.,
McGue and Iacono, 2005). A general propensity to drug use could influence an individual’s
risk to use both inhalants and other substances and cause the use of these substances to be
correlated.
These findings should be interpreted with caution. First, because of the cross-sectional design,
causal inferences are not warranted. Second, some respondents were asked to recall prior drug
use over lengthy periods of time, which, due to forgetfulness, may result in distortions in their
responses. Third, these findings cannot be generalized to adults who were institutionalized or
homeless because they were not covered by the NESARC. A small subgroup of heavy inhalant
users might not have been sampled or were unable to participate in a household survey due to
neurological or other disability from chronic inhalant use (e.g., Anderson and Loomis, 2003).
These limitations aside, this study demonstrates a high prevalence of SUDs among adults who
report a history of inhalant use. Given that young inhalant users may be at risk for injection
drug use and developing multiple SUDs (Wu and Howard, 2007b; Wu et al., 2005), additional
studies are needed to advance our understanding of the progression from inhalant use to drug
use disorders, and to develop effective interventions targeting inhalant users.
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Lifetime prevalence of substance use disorders among lifetime inhalant users compared with
lifetime drug users without a history of inhalant use (other drug users) and respondents without
a history of inhalant and other drug use (non-drug users) in 2001–2002 NESARC (N = 43,093).
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Table 4
Adjusted odds ratios (AORs) and 95 percent confidence intervals (CIs) of past-year substance use disorders








Independent variables AOR (95% CIs) AOR (95% CIs) AOR (95% CIs)
Age group (vs. 45 or older)
 18–29 4.6 (2.45 8.77) 7.8 (3.26 18.47) 2.1 (1.20 3.74)
 30–44 2.0 (1.09 3.62) 1.5 (0.64 3.70) 1.6 (0.99 2.65)
Sex (vs. female)
 Male 1.9 (1.10 3.10) 1.7 (0.84 3.42) 0.9 (0.56 1.30)
Race/ethnicity (vs. white)
 African American 1.1 (0.52 2.24) 1.9 (0.69 4.94) 0.7 (0.32 1.73)
 American Indian/Alaska Native/
Asian
0.9 (0.41 2.06) 0.7 (0.23 1.85) 0.9 (0.37 2.20)
 Hispanic 0.9 (0.42 1.97) 0.8 (0.31 1.95) 0.5 (0.23 0.98)
Education (vs. college)
 < high school 0.8 (0.37 1.68) 1.5 (0.64 3.49) 1.5 (0.78 2.77)
 High school 0.7 (0.39 1.08) 2.0 (1.05 3.69) 0.9 (0.59 1.51)
Marital status (vs. married)
 Widowed/divorced/separated 1.2 (0.67 2.27) 1.8 (0.78 3.93) 1.5 (0.91 2.38)
 Single 1.3 (0.71 2.33) 1.8 (0.97 3.52) 1.1 (0.58 1.96)
Family income (vs. $75,000+)
 $0–$19,999 2.5 (1.16 5.37) 2.8 (1.09 6.95) 4.0 (2.01 7.80)
 $20,000–$39,999 2.4 (1.25 4.71) 1.3 (0.48 3.58) 1.6 (0.82 3.03)
 $40,000–$74,999 1.5 (0.76 2.77) 2.2 (0.81 5.88) 1.2 (0.65 2.15)
Urbanicity (vs. metropolitan–in central city)
 Non-metropolitan areas 1.4 (0.65 2.82) 0.9 (0.41 2.17) 1.5 (0.77 3.04)
 Metropolitan–not in central city 1.3 (0.80 2.15) 0.8 (0.42 1.45) 1.3 (0.85 1.98)
Age of onset of inhalant use (vs. 18)
 < 13 years 0.8 (0.34 1.81) 1.1 (0.35 3.36) 0.9 (0.41 1.84)
 13–17 1.4 (0.92 1.98) 1.4 (0.80 2.37) 1.6 (1.02 2.62)
Personal history of substance abuse treatment (vs. no)
 Yes 0.9 (0.33 2.29) 2.2 (0.79 6.23) 1.3 (0.55 2.94)
Family history of psychopathology (vs. no)
 Yes 1.2 (0.67 2.11) 2.0 (0.98 4.22) 1.3 (0.78 2.05)
a
Each adjusted logistic regression model included all variables listed in the first column; past-year inhalant use disorders were not reported due to a small
number of respondents with a past-year inhalant use disorder.
b
Drug use disorder included any of the nine drug use disorders: inhalant, marijuana, cocaine, heroin, hallucinogen, opioid, sedative, stimulant, and
tranquilizer.
Boldface: p ≤ 0.05.
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